Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ADX-626

Oligonucleotide (siRNA) · Gene silencing · developed by ADARx Pharmaceuticals

Phase 1 Most advanced trial

ADRX Developer

1 Registered trials

What is ADX-626?

ADX-626 is an investigational oligonucleotide studied in Healthy Adult Participants.

At a glance

Drug type: Oligonucleotide (siRNA)
Mechanism: Gene silencing
Developer: ADARx Pharmaceuticals, Inc. (ADRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07081503	Phase 1	Healthy Adult Participants	Recruiting	ADRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Adult Participants

More from ADARx Pharmaceuticals

ADX-038 Phase 1/2 ADX-324 Phase 3 ADX-850 Phase 1

Sources

ClinicalTrials.gov NCT07081503

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADRX page.

Follow ADRX, the company behind ADX-626

See ADRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z